Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder
- PMID:15107657
- DOI: 10.1097/00004850-200405000-00005
Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder
Erratum in
- Int Clin Psychopharmacol. 2004 Jul;19(4):255
Abstract
Escitalopram is the S-enantiomer of citalopram. In this study, we compared the efficacy of equivalent dosages of escitalopram and citalopram in the treatment of moderate to severe major depressive disorder (MDD), based on data from two, pooled, randomized, double-blind, placebo-controlled studies of escitalopram in which citalopram was the active reference. The primary efficacy parameter was the mean change from baseline in the Montgomery Asberg Depression Rating Scale (MADRS) total score. Significant differences in favour of escitalopram were observed for the MADRS [P<0.05, observed cases (OC)/last observation carried forward (LOCF)] and Clinical Global Improvement-Severity of Illness scores (CGI-S; P<0.05, OC/LOCF). Escitalopram separated from placebo at week 1 on the primary efficacy parameter, whereas citalopram first separated from placebo at week 6. An analysis of time to response showed that escitalopram-treated patients responded significantly faster to treatment than citalopram-treated patients (P<0.01). More patients responded to and achieved remission with escitalopram than to citalopram (P<0.05, OC). The HAMD scale was only used in the fixed-dose study, where escitalopram-treated patients had a significant reduction in HAMD-17 total score at week 8 compared to citalopram-treated patients (P<0.05, OC/LOCF). In the pooled subpopulation of severely ill patients (MADRS> or = 30), escitalopram-treated patients showed greater improvement than citalopram-treated patients (P<0.05, LOCF/OC). Escitalopram showed consistently superior efficacy compared to citalopram in the treatment of moderate to severe MDD on all efficacy parameters, and was similarly well tolerated.
Similar articles
- Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.Yevtushenko VY, et al.Clin Ther. 2007 Nov;29(11):2319-32. doi: 10.1016/j.clinthera.2007.11.014.Clin Ther. 2007.PMID:18158074Clinical Trial.
- Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C.Khan A, et al.Clin Drug Investig. 2007;27(7):481-92. doi: 10.2165/00044011-200727070-00005.Clin Drug Investig. 2007.PMID:17563128Clinical Trial.
- [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].Azorin JM, Llorca PM, Despiegel N, Verpillat P.Azorin JM, et al.Encephale. 2004 Mar-Apr;30(2):158-66. doi: 10.1016/s0013-7006(04)95427-9.Encephale. 2004.PMID:15107719Clinical Trial.French.
- Escitalopram : a review of its use in the management of major depressive and anxiety disorders.Waugh J, Goa KL.Waugh J, et al.CNS Drugs. 2003;17(5):343-62. doi: 10.2165/00023210-200317050-00004.CNS Drugs. 2003.PMID:12665392Review.
- [Escitalopram for treatment of major depressive disorder in adults].Llorca PM, Brousse G, Schwan R.Llorca PM, et al.Encephale. 2005 Jul-Aug;31(4 Pt 1):490-501. doi: 10.1016/s0013-7006(05)82410-8.Encephale. 2005.PMID:16389716Review.French.
Cited by
- Citalopram versus other anti-depressive agents for depression.Cipriani A, Purgato M, Furukawa TA, Trespidi C, Imperadore G, Signoretti A, Churchill R, Watanabe N, Barbui C.Cipriani A, et al.Cochrane Database Syst Rev. 2012 Jul 11;2012(7):CD006534. doi: 10.1002/14651858.CD006534.pub2.Cochrane Database Syst Rev. 2012.PMID:22786497Free PMC article.Review.
- Escitalopram versus citalopram: the surprising role of the R-enantiomer.Sánchez C, Bøgesø KP, Ebert B, Reines EH, Braestrup C.Sánchez C, et al.Psychopharmacology (Berl). 2004 Jul;174(2):163-76. doi: 10.1007/s00213-004-1865-z.Psychopharmacology (Berl). 2004.PMID:15160261Review.
- Searching for new drugs for the treatment of dementia-related psychosis.Zakrzewska-Sito A, Kuczyńska J.Zakrzewska-Sito A, et al.Postep Psychiatr Neurol. 2021 Dec;30(4):270-277. doi: 10.5114/ppn.2021.111942. Epub 2021 Dec 21.Postep Psychiatr Neurol. 2021.PMID:37082556Free PMC article.Review.
- Escitalopram: a review of its use in the management of major depressive disorder.Murdoch D, Keam SJ.Murdoch D, et al.Drugs. 2005;65(16):2379-404. doi: 10.2165/00003495-200565160-00013.Drugs. 2005.PMID:16266205Review.
- Stereoselectivity in the Membrane Transport of Phenylethylamine Derivatives by Human Monoamine Transporters and Organic Cation Transporters 1, 2, and 3.Gebauer L, Rafehi M, Brockmöller J.Gebauer L, et al.Biomolecules. 2022 Oct 18;12(10):1507. doi: 10.3390/biom12101507.Biomolecules. 2022.PMID:36291716Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources